Volitionrx (VNRX) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $0.19, +5.56% vs the prior close of $0.18.
- Volume 1.41M shares, 0.1x its 50-day average (light).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
VNRX jumps 5.6% to $0.19. Closed at $0.19, +5.56% vs the prior close of $0.18. Day range $0.18–$0.19, opened at $0.18.
VNRX daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — VNRX jumps 5.6% to $0.19
- Closed at $0.19, +5.56% vs the prior close of $0.18. Day range $0.18–$0.19, opened at $0.18.
- Volume was 1.41M shares, 0.1x its 50-day average of 10.84M — lighter than usual.
- Price is -48.1% vs its 50-day average ($0.37) and -92.4% vs its 200-day average ($2.49).
- 52-week range $0.17–$10.40; today's close sits at 0% of that range, 98.2% below the 52-week high.
Oct 14, 2026 — VNRX ends flat (+0.0%) to $0.18, 6 down days in a row
- Closed at $0.18, +0.00% vs the prior close of $0.18. Day range $0.17–$0.18, opened at $0.18.
- Volume was 993.20K shares, 0.1x its 50-day average of 10.82M — lighter than usual.
- Price is -52.4% vs its 50-day average ($0.38) and -92.8% vs its 200-day average ($2.51).
- 52-week range $0.17–$10.40; today's close sits at 0% of that range, 98.3% below the 52-week high.
- That makes 6 straight losses.
Oct 13, 2026 — VNRX slides 10.0% to $0.18, a 52-week low, 5 down days in a row
- Closed at $0.18, -10.00% vs the prior close of $0.20. Day range $0.18–$0.21, opened at $0.20.
- Volume was 1.84M shares, 0.2x its 50-day average of 10.79M — lighter than usual.
- Price is -53.9% vs its 50-day average ($0.39) and -92.9% vs its 200-day average ($2.53).
- 52-week range $0.18–$10.40; today's close sits at 0% of that range, 98.3% below the 52-week high.
- That makes 5 straight losses.
Oct 12, 2026 — VNRX slides 4.8% to $0.20, a 52-week low, 4 down days in a row
- Closed at $0.20, -4.76% vs the prior close of $0.21. Day range $0.20–$0.22, opened at $0.22.
- Volume was 771.70K shares, 0.1x its 50-day average of 10.78M — lighter than usual.
- Price is -50.3% vs its 50-day average ($0.40) and -92.2% vs its 200-day average ($2.56).
- 52-week range $0.20–$10.40; today's close sits at 0% of that range, 98.1% below the 52-week high.
- That makes 4 straight losses.
Oct 9, 2026 — VNRX slides 4.5% to $0.21, a 52-week low, 3 down days in a row
- Closed at $0.21, -4.55% vs the prior close of $0.22. Day range $0.21–$0.23, opened at $0.22.
- Volume was 1.08M shares, 0.1x its 50-day average of 10.78M — lighter than usual.
- Price is -49.2% vs its 50-day average ($0.41) and -91.9% vs its 200-day average ($2.58).
- 52-week range $0.21–$12.80; today's close sits at 0% of that range, 98.4% below the 52-week high.
- That makes 3 straight losses.
Oct 8, 2026 — VNRX slides 4.3% to $0.22, a 52-week low
- Closed at $0.22, -4.35% vs the prior close of $0.23. Day range $0.22–$0.23, opened at $0.23.
- Volume was 825.50K shares, 0.1x its 50-day average of 10.77M — lighter than usual.
- Price is -48.2% vs its 50-day average ($0.42) and -91.6% vs its 200-day average ($2.61).
- 52-week range $0.22–$13.40; today's close sits at 0% of that range, 98.4% below the 52-week high.
Oct 7, 2026 — VNRX slides 4.2% to $0.23
- Closed at $0.23, -4.17% vs the prior close of $0.24. Day range $0.22–$0.24, opened at $0.24.
- Volume was 1.35M shares, 0.1x its 50-day average of 10.75M — lighter than usual.
- Price is -47.2% vs its 50-day average ($0.44) and -91.3% vs its 200-day average ($2.63).
- 52-week range $0.22–$13.40; today's close sits at 0% of that range, 98.3% below the 52-week high.
Oct 6, 2026 — VNRX jumps 4.3% to $0.24
- Closed at $0.24, +4.35% vs the prior close of $0.23. Day range $0.23–$0.25, opened at $0.23.
- Volume was 642.60K shares, 0.1x its 50-day average of 10.74M — lighter than usual.
- Price is -46.5% vs its 50-day average ($0.45) and -91.0% vs its 200-day average ($2.66).
- 52-week range $0.23–$13.40; today's close sits at 0% of that range, 98.2% below the 52-week high.
Oct 5, 2026 — VNRX slides 4.2% to $0.23
- Closed at $0.23, -4.17% vs the prior close of $0.24. Day range $0.23–$0.24, opened at $0.23.
- Volume was 713.10K shares, 0.1x its 50-day average of 10.73M — lighter than usual.
- Price is -50.1% vs its 50-day average ($0.46) and -91.4% vs its 200-day average ($2.68).
- 52-week range $0.23–$13.40; today's close sits at 0% of that range, 98.3% below the 52-week high.
Oct 2, 2026 — VNRX jumps 4.3% to $0.24
- Closed at $0.24, +4.35% vs the prior close of $0.23. Day range $0.23–$0.24, opened at $0.24.
- Volume was 1.38M shares, 0.1x its 50-day average of 10.71M — lighter than usual.
- Price is -49.6% vs its 50-day average ($0.48) and -91.1% vs its 200-day average ($2.71).
- 52-week range $0.23–$13.40; today's close sits at 0% of that range, 98.2% below the 52-week high.
VNRX latest news & SEC filings
Every SEC filing by or about VNRX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 30, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Forterre Gael had withheld for taxes 284 shares at $0.25 (≈$72) on Sep 28, 2026; now holds 16,284
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 30, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Michel Gaetan had withheld for taxes 608 shares at $0.25 (≈$154) on Sep 28, 2026; now holds 12,232
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 25, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 3.02 — Sold unregistered shares.
Sep 16, 2026 · SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Sep 15, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 3.02 — Sold unregistered shares.
Sep 14, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Sep 4, 2026 · SCHEDULE 13D — Activist-style stake (13D)
Activist-style stake (13D) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Sep 2, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
Sep 2, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 3.02 — Sold unregistered shares.
Aug 28, 2026 · S-3 — Shelf registration (S-3)
Shelf registration (S-3) — lets the company sell securities over time
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 24, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 3.02 — Sold unregistered shares.
Aug 21, 2026 · S-8 — Registration of shares for employee stock plans (S-8)
Registration of shares for employee stock plans (S-8)
Things to know before you trade VNRX
- Last results release: Aug 13, 2026 (8-K Item 2.02). Previous ones: May 14, 2026, Mar 31, 2026, Nov 13, 2025. Based on that rhythm, the next report is likely around Nov 12, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 4.03% (largest 11.5%). That is a volatile stock.
- Liquidity: about 1.91M shares (≈$362.67K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $0.19 vs a range of $0.17–$10.40 (0% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: 1:20 on Apr 28, 2026
- Insider trades (Form 4, last 12 months, recent 25 shown): 4 open-market buys, 0 sales; latest: Cameron John Reynolds bought 20,000 shares on Nov 17, 2025.
- Latest filings: 8-K Sep 25, 2026; 8-K Sep 15, 2026; 8-K Sep 14, 2026.
- Share count: 13.65M shares outstanding (Aug 11, 2026), -87.3% vs a year earlier — the company has been reducing its share count.
- Listing: NYSE · industry: In Vitro & In Vivo Diagnostic Substances.
VNRX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 0.18 | 0.19 | 0.18 | 0.19 | 1.41M |
| Oct 14, 2026 | 0.18 | 0.18 | 0.17 | 0.18 | 993.20K |
| Oct 13, 2026 | 0.20 | 0.21 | 0.18 | 0.18 | 1.84M |
| Oct 12, 2026 | 0.22 | 0.22 | 0.20 | 0.20 | 771.70K |
| Oct 9, 2026 | 0.22 | 0.23 | 0.21 | 0.21 | 1.08M |
| Oct 8, 2026 | 0.23 | 0.23 | 0.22 | 0.22 | 825.50K |
| Oct 7, 2026 | 0.24 | 0.24 | 0.22 | 0.23 | 1.35M |
| Oct 6, 2026 | 0.23 | 0.25 | 0.23 | 0.24 | 642.60K |
| Oct 5, 2026 | 0.23 | 0.24 | 0.23 | 0.23 | 713.10K |
| Oct 2, 2026 | 0.24 | 0.24 | 0.23 | 0.24 | 1.38M |
| Oct 1, 2026 | 0.25 | 0.26 | 0.23 | 0.23 | 8.13M |
| Sep 30, 2026 | 0.26 | 0.26 | 0.25 | 0.26 | 1.44M |
| Sep 29, 2026 | 0.25 | 0.26 | 0.25 | 0.26 | 2.10M |
| Sep 28, 2026 | 0.25 | 0.26 | 0.24 | 0.25 | 906.00K |
| Sep 25, 2026 | 0.25 | 0.26 | 0.23 | 0.26 | 2.89M |
| Sep 24, 2026 | 0.24 | 0.25 | 0.24 | 0.25 | 893.50K |
| Sep 23, 2026 | 0.26 | 0.26 | 0.23 | 0.25 | 2.84M |
| Sep 22, 2026 | 0.26 | 0.26 | 0.26 | 0.26 | 1.72M |
| Sep 21, 2026 | 0.26 | 0.26 | 0.26 | 0.26 | 1.86M |
| Sep 18, 2026 | 0.28 | 0.28 | 0.24 | 0.26 | 4.37M |
About Volitionrx
Volitionrx (VNRX) is listed on the NYSE and classified by the SEC under “In Vitro & In Vivo Diagnostic Substances”. Its business address is in HENDERSON, NV. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 93314.
VNRX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Phillip Barnes | Director | Jan 23, 2026 |
| Alan Colman | Director | Jan 23, 2026 |
| Mickie Henshall | Director | Jan 23, 2026 |
| Guy Archibald Innes | Director | Feb 27, 2026 |
| Kim Nguyen | Director | Feb 27, 2026 |
| Cameron John Reynolds | President and CEO | Feb 27, 2026 |
| Ethel Rubin | Director | Feb 27, 2026 |
| Timothy I Still | Director | Jan 23, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Ann-Louise Batchelor | Group Chief Marketing Officer | Feb 27, 2026 |
| Salvatore Thomas Butera | CEO - Volition Veterinary | Jan 23, 2026 |
| Gael Forterre | Chief Commercial Officer | Sep 30, 2026 |
| Terig Hughes | Chief Financial Officer | Feb 27, 2026 |
| Jasmine Kway | CEO - Singapore Volition | Feb 27, 2026 |
| Jacob Vincent Micallef | Chief Scientific Officer | Mar 19, 2026 |
| Gaetan Michel | Chief Operating Officer | Sep 30, 2026 |
| Nicholas Plummer | GC - Volition Diagnostics | Mar 19, 2026 |
| Andrew Retter | Chief Medical Officer | Nov 4, 2025 |
| Cameron John Reynolds | President and CEO | Feb 27, 2026 |
| Rodney Gerard Rootsaert | Secretary | Mar 19, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Nov 17, 2025 | Cameron John Reynolds | Buy | 20,000 | $0.35 |
| Oct 14, 2025 | Cameron John Reynolds | Buy | 110,000 | $0.51 |
| Oct 14, 2025 | Timothy I Still | Buy | 48,076 | $0.51 |
| Oct 14, 2025 | Guy Archibald Innes | Buy | 96,153 | $0.51 |
VNRX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $1.73M | $-23.36M | — | $-19.68M |
| Dec 31, 2024 | $1.23M | $-26.97M | -0.31 | $-25.89M |
| Dec 31, 2023 | $775.30K | $-35.68M | -0.50 | $-18.06M |
| Dec 31, 2022 | $306.39K | $-30.60M | — | $-15.28M |
| Dec 31, 2021 | $90.03K | $-26.99M | — | $-20.85M |
Latest balance sheet: total assets $8.30M, total liabilities $41.84M, cash $2.80M (as of Jun 30, 2026).
VNRX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 13, 2026 | 8-K Item 2.02 (results) | $0.63 |
| May 14, 2026 | 8-K Item 2.02 (results) | $2.20 |
| Mar 31, 2026 | 8-K Item 2.02 (results) | $4.00 |
| Nov 13, 2025 | 8-K Item 2.02 (results) | $7.00 |
| Oct 14, 2025 | 8-K Item 2.02 (results) | $9.20 |
| Aug 14, 2025 | 8-K Item 2.02 (results) | $12.80 |
| May 15, 2025 | 8-K Item 2.02 (results) | $9.00 |
| Mar 31, 2025 | 8-K Item 2.02 (results) | $11.40 |
| Nov 14, 2024 | 8-K Item 2.02 (results) | $14.40 |
| Aug 14, 2024 | 8-K Item 2.02 (results) | — |
| May 13, 2024 | 8-K Item 2.02 (results) | — |
| Mar 25, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · In Vitro & In Vivo Diagnostic Substances
Idexx Laboratories (IDXX)Lantheus (LNTH)Intellia Therapeutics (NTLA)Neogen (NEOG)Celldex Therapeutics (CLDX)QuidelOrtho (QDEL)Achieve Life Sciences (ACHV)Myriad Genetics (MYGN)Alpha Teknova (TKNO)Insight Molecular Diagnostics (IMDX)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on VNRX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.